Rapport Therapeutics, Inc. (RAPP) Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Rapport Therapeutics, Inc. Common Stock NASDAQ:RAPP Healthcare · Biotechnology
Mkt Cap $1.41B
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release ● Major ⚠ 3
Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement
Rapport Therapeutics priced roughly $355 million in gross capital: a $175M common stock offering at $21.00 per share plus $25M of pre-funded warrants, $150M of 2.25% convertible senior notes due 2032, and a $30M concurrent private placement at the same offering price.
Expected net proceeds total approximately $360.7 million across the three tranches, with the initial note conversion price set at $26.7750 — a 27.50% premium to the offering price.
Proceeds will primarily fund ongoing and planned clinical trials of lead asset RAP-219, and the company says the raise extends its cash runway through the end of 2029.
• 4d ago AI analysis › Press Release ● Major ⚠ 4
Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement
Rapport Therapeutics launched a dual capital raise: a $200M underwritten public offering of common stock and a $150M convertible senior notes offering due 2032, plus a concurrent private placement with a single investor priced off the equity deal.
Underwriters hold 30-day options for up to an additional $30M of shares and $22.5M of notes, meaning total raise could exceed $400M if over-allotments are exercised.
Proceeds fund ongoing and planned clinical trials of lead asset RAP-219 (epilepsy, bipolar mania), plus R&D, working capital, and possible in-licensing or acquisitions. Morgan Stanley, Leerink Partners, and Evercore ISI are lead book-runners.
• 5d ago AI analysis › Press Release ● Major ⚠ 3
Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania
Rapport Therapeutics reported positive topline Phase 2 results for RAP-219 in acute bipolar mania, meeting the primary endpoint with a statistically significant 3.1-point placebo-adjusted YMRS improvement at Week 3 (p=0.045) and the CGI-BP secondary endpoint (0.4 points, p=0.024).
RAP-219 was well tolerated, with TEAE rates similar to placebo (51.6% vs 52.8%), no severe TEAEs or SAEs, and an absence of somnolence, akathisia, and extrapyramidal symptoms common to existing mania therapies.
The company plans an FDA End-of-Phase 2 meeting in Q1 2027 and initiation of two Phase 3 bipolar mania trials in 2H 2027, alongside ongoing Phase 3 epilepsy programs. With $436.1 million in cash funding operations into 2H 2029, the pipeline and cash runway support execution through key data readouts.
• 12d ago AI analysis › Press Release
Rapport Therapeutics to Participate in Upcoming Investor Conferences
Rapport Therapeutics announced that management will participate in two upcoming investor events: a fireside chat at the Cantor Global Healthcare Conference in New York on September 9, 2026, and a virtual fireside chat at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026.
Live and archived webcasts of both fireside chats will be accessible in the Investors section of the company's website.
Rapport is a clinical-stage biotechnology company developing small molecule precision medicines for neurological and psychiatric disorders, anchored by lead investigational drug RAP-219 and its epilepsy portfolio. The release contains no new clinical, financial, or strategic disclosures and is routine IR scheduling.
• 1mo ago AI analysis › Press Release
Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program
Rapport Therapeutics announced it will host a virtual Key Opinion Leader (KOL) event on September 22, 2026, featuring experts Dr. Mauricio Tohen and Dr. Gary Sachs to discuss the unmet need in bipolar mania.
The event will focus on the mechanistic rationale for RAP-219, the Company's TARPγ8-specific AMPA receptor negative allosteric modulator currently in development.
Management noted that topline data from the ongoing Phase 2 trial of RAP-219 in bipolar mania is expected in October 2026.
• 2mo ago AI analysis › Press Release ● Major ⚠ 2
Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update
Rapport Therapeutics initiated the Phase 3 program for RAP-219 in focal onset seizures, with the FOCUS 1 and FOCUS 2 trials now enrolling patients, and reported an 80% median reduction in long episodes in follow-up Phase 2a data.
The company received IND approval in China for the Phase 3 FOS trials and remains on track for topline results from its Phase 2 bipolar mania trial in October 2026.
Rapport ended the second quarter of 2026 with $436.1 million in cash and investments, providing a runway into the second half of 2029, despite a net loss of $56.6 million driven by increased R&D spending.
• 2mo ago AI analysis › Press Release
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
Rapport Therapeutics announced that management will participate in two upcoming investor conferences in June 2026.
The company will hold a fireside chat at the Jefferies Global Healthcare Conference in New York on June 3 and at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on June 8.
Live and archived webcasts of these sessions will be available on the company’s investor relations website.
• 5mo ago AI analysis › Press Release ● Major
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
Rapport Therapeutics reported robust Phase 2a follow-up data for RAP-219, showing a 90% median reduction in clinical seizures over baseline and an updated 22-day half-life, supporting the planned Phase 3 initiation in Q2 2026.
The company accelerated its Bipolar Mania Phase 2 topline timeline to Q4 2026 and signed a strategic collaboration with Tenacia Biotechnology, which contributed $20.0 million in Q1 revenue.
Financially, Rapport ended Q1 with $476.8 million in cash, sufficient to fund operations into the second half of 2029, while narrowing its net loss to $19.9 million compared to the prior year.
• 5mo ago AI analysis › Press Release
MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025
globenewswire.com • 6mo ago Press Release ● Major
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting
Rapport Therapeutics presented positive Phase 2a follow-up data for RAP-219, showing a 90% median reduction in clinical seizures in weeks 9-12 and 59% in weeks 13-16.
The study confirmed an extended 22-day half-life, supporting sustained therapeutic exposure and efficacy without new safety signals during the off-treatment period.
Based on these results, management expects to initiate two pivotal Phase 3 trials (FOCUS 1 and FOCUS 2) in the second quarter of 2026.
• 6mo ago AI analysis › 
